본문 바로가기
KERD
논문KCI 등재

SARS-CoV-2 Variants of Concern

최준용|Davey M. Smith
연세대학교의과대학 (Yonsei University College of Medicine)|2021.11|Yonsei Medical Journal|제62권 제11호|pp. 961-968|DOI 10.3349/ymj.2021.62.11.961

1

조회

0

다운로드

5

인용

0

참고문헌

키워드

COVID-19vaccineSARS-CoV-2variantvariant of concerndelta variantalpha variant
주제분류의학일반

초록

Since the COVID-19 pandemic first began in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has continuously evolved with many variants emerging across the world. These variants are categorized as the variant of interest (VOI), variant of concern (VOC), and variant under monitoring (VUM). As of September 15, 2021, there are four SARS-CoV-2 lineages designated as the VOC (alpha, beta, gamma, and delta variants). VOCs have increased transmissibility compared to the original virus, and have the potential for increasing disease severity. In addition, VOCs exhibit decreased susceptibility to vaccineinduced and infection-induced immune responses, and thus possess the ability to reinfect previously infected and recovered individuals. Given their ability to evade immune responses, VOC are less susceptible to monoclonal antibody treatments. VOCs can also impact the effectiveness of mRNA and adenovirus vector vaccines, although the currently authorized COVID-19 vaccines are still effective in preventing infection and severe disease. Current measures to reduce transmission as well as efforts to monitor andunderstand the impact of variants should be continued. Here, we review the molecular features, epidemiology, impact on transmissibility, disease severity, and vaccine effectiveness of VOCs.

Abstract

Since the COVID-19 pandemic first began in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has continuously evolved with many variants emerging across the world. These variants are categorized as the variant of interest (VOI), variant of concern (VOC), and variant under monitoring (VUM). As of September 15, 2021, there are four SARS-CoV-2 lineages designated as the VOC (alpha, beta, gamma, and delta variants). VOCs have increased transmissibility compared to the original virus, and have the potential for increasing disease severity. In addition, VOCs exhibit decreased susceptibility to vaccineinduced and infection-induced immune responses, and thus possess the ability to reinfect previously infected and recovered individuals. Given their ability to evade immune responses, VOC are less susceptible to monoclonal antibody treatments. VOCs can also impact the effectiveness of mRNA and adenovirus vector vaccines, although the currently authorized COVID-19 vaccines are still effective in preventing infection and severe disease. Current measures to reduce transmission as well as efforts to monitor andunderstand the impact of variants should be continued. Here, we review the molecular features, epidemiology, impact on transmissibility, disease severity, and vaccine effectiveness of VOCs.

참고문헌 (61)

  1. Sui J, "Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway", PLoS Pathog, 4, pp.e1000197~ (2008)
  2. Gupta RK, "Will SARS-CoV-2 variants of concern affect the promise of vaccines?", Nat Rev Immunol, 21, pp.340~341 (2021)
  3. Avanzato VA, "Case study : prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer", Cell, 183, pp.1901~1912 (2020)
  4. Kemp SA, "SARS-CoV-2 evolution during treatment of chronic infection", Nature, 592, pp.277~282 (2021)
  5. Groves DC, "The D614G mutations in the SARS-CoV-2 spike protein : implications for viral infectivity, disease severity and vaccine design", Biochem Biophys Res Commun, 538, pp.104~107 (2021)
  6. Korber B, "Tracking changes in SARS-CoV-2 spike : evidence that D614G increases infectivity of the COVID-19 virus", Cell, 182, pp.812~827 (2020)
  7. "WHO announces simple, easy-to-say labels for SARS-CoV-2 variants of interest and concern"[URL]
  8. "Tracking SARS-CoV-2 variants"[URL]
  9. "Weekly epidemiological update on COVID-19 - 31 August 2021"[URL]
  10. "Investigation of novel SARS-CoV-2 variant:variant of concern 202012/01: techinical briefing 3"[URL]
  11. A Chaillon, "Phylogenetic Analyses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.1.7 Lineage Suggest a Single Origin Followed by Multiple Exportation Events Versus Convergent Evolution", Clinical Infectious Diseases, 73(12), pp.2314~2317 (2021), Oxford University Press (OUP)[DOI]
  12. Davies NG, "Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England", Science, 372, pp.eabg3055~ (2021)
  13. Starr TN, "Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding", Cell, 182, pp.1295~1310 (2020)
  14. Peacock TP, "The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets", Nat Microbiol, 6, pp.899~909 (2021)
  15. Meng B, "Recurrent emergence of SARS-CoV-2 spike deletion H69", V70 and its role in the Alpha variant B.1.1.7, 2021, pp.35, 109292~
  16. "NERVTAG paper on COVID-19 variant of concern B.1.1.7"[URL]
  17. Chen RE, "Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies", Nat Med, 27, pp.717~726 (2021)
  18. Ho D, "Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization", Research Square (2021)[DOI]
  19. Collier DA, "Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies", Nature, 593, pp.136~141 (2021)
  20. Liu Y, "Neutralizing activity of BNT162b2-elicited serum", N Engl J Med, 384, pp.1466~1468 (2021)
  21. "Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants" (2021)[URL]
  22. Lopez Bernal J, "Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant", N Engl J Med, 385, pp.585~594 (2021)
  23. Chemaitelly H, "mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar", Nat Med, 27, pp.1614~1621 (2021)
  24. Mahase E, "Covid-19 : Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant", BMJ, 372, pp.n296~ (2021)
  25. Graham MS, "Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study", Lancet Public Health, 6, pp.e335~45 (2021)
  26. Tegally H, "Detection of a SARS-CoV-2 variant of concern in South Africa", Nature, 592, pp.438~443 (2021)
  27. Tang JW, "Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK", J Infect, 82, pp.e8~10 (2021)
  28. Khan A, "Higher infectivity of the SARS-CoV-2 new variants is associated with K417N", T, E484K, and N501Y mutants : an insight from structural data, 2021, pp.236, 7045~7057
  29. Ramanathan M, "SARS-CoV-2B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity", Lancet Infect Dis, 21, pp.1070~ (2021)
  30. Arena F, "Summary of the available molecular methods for detection of SARS-CoV-2 during the ongoing pandemic", Int J Mol Sci, 22, pp.1298~ (2021)
  31. Jangra S, "SARS-CoV-2 spike E484K mutation reduces antibody neutralisation", Lancet Microbe, 2, pp.e283~4 (2021)
  32. "Estimates of severity and transmissibility of novel South Africa SARSCoV-2 variant 501Y.V2"[URL]
  33. Funk T, "Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351or P.1: data from seven EU", EEA countries, weeks 38, 2021, pp.Euro Surveill (2020), 2021[DOI]
  34. Wibmer CK, "SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma", Nat Med, 27, pp.622~625 (2021)
  35. Cele S, "Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma", Nature, 593, pp.142~146 (2021)
  36. "Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab"[URL]
  37. Wang Z, "mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants", Nature, 592, pp.616~622 (2021)
  38. Xie X, "Neutralization of SARS-CoV-2 spike 69", 70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera, 2021, pp.27, 620~621
  39. Fujino T, "Novel SARS-CoV-2 variant in travelers from Brazil to Japan", Emerg Infect Dis, 27, pp.1243~1245 (2021)
  40. Naveca FG, "COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence", Nat Med, 27, pp.1230~1238 (2021)
  41. "Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil" (2021)[URL]
  42. Sabino EC, "Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence", Lancet, 397, pp.452~455 (2021)
  43. "Fact sheet for health care providers emergency use authorization (EUA) of REGEN-COVTM (casirivimab and imdevimab)"[URL]
  44. Wang P, "Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization", Cell Host Microbe, 29, pp.747~751 (2021)
  45. Charmet T, "Impact of original, B.1.1.7, and B.1.351", P.1 SARS-CoV-2lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: results from a nationwide case-control study in France, 2021, pp.8, 100171~
  46. "Genome sequencing by INSACOG shows variants of concern and a novel variant in India"[URL]
  47. "SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 10"[URL]
  48. "WHO: Delta now dominant COVID variant globally"[URL]
  49. Chen J, "Mutations strengthened SARSCoV-2 infectivity", J Mol Biol, 432, pp.5212~5226 (2020)
  50. Teng S, "Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity", Brief Bioinform, 22, pp.1239~1253 (2021)
  51. Deng X, "Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant", Cell, 184, pp.3426~3437 (2021)
  52. "Increased household transmission of COVID-19 cases associated with SARS-CoV-2 variant of concern B.1.617.2: a national case-control study"[URL]
  53. "Modelling importations and local transmission of B.1.617.2 in the UK"[URL]
  54. "Potential community transmission of B.1.617.2 inferred by S-gene positivity"[URL]
  55. Dougherty K, "SARS-CoV-2B.1.617. 2 (Delta) variant COVID-19 outbreak associated with a gymnastics facility—Oklahoma, April–May 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1004~1007 (2021)
  56. Madewell ZJ, "Household transmission of SARS-CoV-2 : a systematic review and meta-analysis", JAMA Netw Open, 3, pp.e2031756~ (2020)
  57. Sean Wei Xiang Ong, "Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)", Clinical Infectious Diseases (2021), Oxford University Press (OUP)[DOI]
  58. "Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada" (2021)[URL]
  59. Planas D, "Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization", Nature, 596, pp.276~280 (2021)
  60. Petra Mlcochova, "SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion", Nature, 599(7883), pp.114~119 (2021), Springer Science and Business Media LLC[DOI]
  61. Sheikh A, "SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness", Lancet, 397, pp.2461~2462 (2021)

관련 논문AI추천

SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask최준용, Davey M. Smith, Dong Hoon Shin연세대학교의과대학 · Yonsei Medical Journal2022 · 제63권 제11호SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene김수현, 박호영, 송창선, 전현정, Hisham Yasmin대한면역학회 · Immune Network2021 · 제21권 제5호Understanding SARS-CoV-2 Variants and Safety Countermeasures for the Fight against Omicron김명류, 홍복실동북아학술저널연합 · International Journal of Crisis & Safety2022 · 제7권 제1호COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants김정기, 송영천, 이종길, Españo Erica, Kim Sang-Hyun, Padasas Bill Thaddeus대한면역학회 · Immune Network2023 · 제23권 제2호SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues김수현, 송창선, 전현정, Choi Yang Kyu, Kim Byoungguk, Kim Sinae, Kim Sung-Han, Kim Yong-Gil, Lee Youngmin, Netea Mihai, Nguyen Tam T., Park Ho-Young, Shin Kyeong-Cheol, Song Eun Young, Taitt Afeisha S., Yeom Su Cheong, Yum Hokee대한면역학회 · Immune Network2021 · 제21권 제6호Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2안대균, Kim Yu-Jin, Lee Su Jin한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2022 · 제32권 제9호

이 간행물의 다른 논문 (8건)

In Vitro Models Mimicking Immune Response in the Skin신정우, 문수진, 김동현pp. 969-980Transcatheter Aortic Valve Replacement with Minimal Contrast Dye in Patients with Renal Insufficiency홍성진, 김병극, 심지영, 안철민, 장양수, 홍명기, 최자연, 김중선, 고영국, 최동훈, 홍그루pp. 990-996Medications and the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Use of the Landmark Method김희만, 이정국, 김현수, 김동욱, 강대용, 최윤영pp. 997-1004Regulation of MUC6 Methylation Correlates with Progression of Gastric CancerXiao-xia Xi, Ding Shipp. 1005-1015Activation of CpG-ODN-Induced TLR9 Signaling Inhibited by Interleukin-37 in U937 Human Macrophages최정윤, 박기연, 김성규pp. 1023-1031
원문 보기